NCT04893915撤回2 期
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Overall response rate (ORR) of recipients
研究概览
简要总结
Patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will receive lymphodepleting chemotherapy (Flu/Cy) and two infusions of cytokine-induced memory-like NK cells at the previously defined maximum tolerated dose (MTD), fourteen days apart. Low dose rhIL-2 will be administered to patients for in vivo expansion following cell infusion. Patients will be assessed for anti-leukemic efficacy and safety. Re-infusion of patients who relapsed after clinical response will be considered.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Refractory AML without CR after induction therapy (primary induction failure); relapsed AML after obtaining a CR; progressive AML after non-intensive therapy (e.g., HMA + venetoclax or targeted therapy); Intermediate risk to very-high-risk MDS by IPSS-R that is relapsed or refractory after prior therapy with an HMA-containing regimen
- •At least 18 years of age.
- •Available allogeneic donor that meets the following criteria:
- •Able and willing to undergo multiple rounds of leukapheresis
- •At least 18 years of age
- •In general good health, and medically able to tolerate leukapheresis required for harvesting the NK cells for this study.
- •Negative for hepatitis, HTLV, and HIV on donor viral screen
- •Not pregnant
- •Voluntary written consent to participate in this study
- •All HLA-match/mismatch statuses will be included, with preference for unmatched donors all else being equal
- •Patients with known CNS involvement with AML are eligible provided that they have been treated and CSF is clear for at least 2 weeks prior to enrollment into the study. CNS therapy (chemotherapy or radiation) should continue as medically indicated during the study treatment.
- •Karnofsky/Lansky performance status > 50 %
- •Adequate organ function as defined below:
- •Total bilirubin < 2 mg/dL
- •AST(SGOT)/ALT(SGPT) < 3.0 x ULN
- •Creatinine within normal institutional limits OR creatinine clearance ≥ 40 mL/min by Cockcroft-Gault Formula
- •Oxygen saturation ≥90% on room air
- •Ejection fraction ≥35%
- •Able to be off corticosteroids and any other immune suppressive medications beginning on Day -3 and continuing until 30 days after the last infusion of the NK cell product. However, use of low-level corticosteroids is permitted if deemed medically necessary. Low-level corticosteroid use is defined as 10mg or less of prednisone (or equivalent for other steroids) per day.
- •Women of childbearing potential must have a negative pregnancy test within 28 days prior to study registration. Female and male patients (along with their female partners) must agree to use two forms of acceptable contraception, including one barrier method, during participation in the study and until 30 days after the last NK cell product infusion.
- •Ability to understand and willingness to sign an IRB approved written informed consent document
排除标准
- •Relapsed after allogeneic transplantation.
- •Circulating blast count >30,000/µL by morphology or flow cytometry (cytoreductive therapies including leukapheresis or hydroxyurea are allowed).
- •Uncontrolled bacterial or viral infections, or known HIV, Hepatitis B or C infection.
- •Uncontrolled angina, severe uncontrolled ventricular arrhythmias, or EKG suggestive of acute ischemia or active conduction system abnormalities.
- •New progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that have not been evaluated with bronchoscopy. Infiltrates attributed to infection must be stable/ improving after 1 week of appropriate therapy (4 weeks for presumed or proven fungal infections).
- •Known hypersensitivity to one or more of the study agents.
- •Received any investigational drugs within the 14 days prior to the first dose of fludarabine.
- •Pregnant and/or breastfeeding.
- •Any condition that, in the opinion of the investigator, would prevent the participant from consenting to or participating in the study
研究组 & 干预措施
Lead In Cohort Recipient: Cytokine-induced memory-like NK cells
Experimental
- Fludarabine and cyclophosphamide beginning on Day -6.
- NK cell product will be infused on Day 0.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
- NK cell product will be infused into the recipient on Day +14.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.
- In the Lead-in Cohort, three patients will receive NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10^6/kg.
- Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0.
干预措施: Cytokine-induced memory-like NK cells (Biological)
Lead In Cohort Recipient: Cytokine-induced memory-like NK cells
Experimental
- Fludarabine and cyclophosphamide beginning on Day -6.
- NK cell product will be infused on Day 0.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
- NK cell product will be infused into the recipient on Day +14.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.
- In the Lead-in Cohort, three patients will receive NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10^6/kg.
- Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0.
干预措施: Fludarabine (Drug)
Lead In Cohort Recipient: Cytokine-induced memory-like NK cells
Experimental
- Fludarabine and cyclophosphamide beginning on Day -6.
- NK cell product will be infused on Day 0.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
- NK cell product will be infused into the recipient on Day +14.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.
- In the Lead-in Cohort, three patients will receive NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10^6/kg.
- Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0.
干预措施: Cyclophosphamide (Drug)
Lead In Cohort Recipient: Cytokine-induced memory-like NK cells
Experimental
- Fludarabine and cyclophosphamide beginning on Day -6.
- NK cell product will be infused on Day 0.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
- NK cell product will be infused into the recipient on Day +14.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.
- In the Lead-in Cohort, three patients will receive NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10^6/kg.
- Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0.
干预措施: Interleukin-2 (Drug)
Phase II Recipient: Cytokine-induced memory-like NK cells
Experimental
- Fludarabine and cyclophosphamide beginning on Day -6.
- NK cell product will be infused on Day 0.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
- NK cell product will be infused into the recipient on Day +14.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.
- Will receive the NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10^6/kg.
- Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0.
干预措施: Cytokine-induced memory-like NK cells (Biological)
Phase II Recipient: Cytokine-induced memory-like NK cells
Experimental
- Fludarabine and cyclophosphamide beginning on Day -6.
- NK cell product will be infused on Day 0.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
- NK cell product will be infused into the recipient on Day +14.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.
- Will receive the NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10^6/kg.
- Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0.
干预措施: Fludarabine (Drug)
Phase II Recipient: Cytokine-induced memory-like NK cells
Experimental
- Fludarabine and cyclophosphamide beginning on Day -6.
- NK cell product will be infused on Day 0.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
- NK cell product will be infused into the recipient on Day +14.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.
- Will receive the NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10^6/kg.
- Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0.
干预措施: Cyclophosphamide (Drug)
Phase II Recipient: Cytokine-induced memory-like NK cells
Experimental
- Fludarabine and cyclophosphamide beginning on Day -6.
- NK cell product will be infused on Day 0.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
- NK cell product will be infused into the recipient on Day +14.
- IL-2 will begin 2-4 hours after infusion and will continue every other day through Day 26 for an additional 7 doses, and a total of 14 doses, to a maximum of two vials of rhIL-2 per IL-2 course.
- Will receive the NK cell product on Day 0 and Day +14, receiving the maximum NK cells generated, capped at 20x10^6/kg.
- Patients that have an initial response but then subsequently relapse or progress will be able to receive a third dose of NK cell product with or without lymphodepleting chemotherapy depending on the interval duration between the second dose and relapse, after approval by the study PI. The third dose should be administered not less than 45 days from Day 0.
干预措施: Interleukin-2 (Drug)
Donor
Experimental
- The allogeneic donor will undergo non-mobilized large volume (20-L) leukapheresis on Day -1.
- On Day +13 the allogeneic donor will again undergo non-mobilized large volume (20-L) leukapheresis
干预措施: Donor Leukapheresis (Procedure)
结局指标
主要结局
Overall response rate (ORR) of recipients
时间窗: Through 12 month follow-up
* Defined as the proportion of patients achieving complete remission (CR), complete remission with partial hematologic recovery (CRh), and complete remission with incomplete blood count recovery (CRi). * Response will be assessed according to the criteria from the International Working Group Response Criteria
次要结局
- Overall survival (OS) of recipients(Through completion of follow-up (estimated to be 12 months))
- Duration of overall response (DOR) of recipients(Through 12 month follow-up)
- Event free survival (EFS) of recipients(Through completion of follow-up (estimated to be 12 months))
- Duration of complete response (DoCR) of recipients(Through 12 month follow-up)
- Proportion of recipients that receive multiple doses of NK cell product(Through Day +14 of all recipients enrolled (estimated to be 19 months))
- Number of dose-limiting toxicities (DLTs) that recipients experience in the safety lead-in cohort(Through Day 28)
- Mortality rate of recipients(Day +100)
- Number of adverse events experienced by recipients(Through Day +100)
- Overall response rate (ORR) of recipients compared across subgroups(Through 12 month follow-up)
- Number of adverse events experienced by recipients compared across subgroups(Through Day +100)
- Proportion of recipients with prolonged cytopenia(At 8 weeks)
- Change in quality of life experienced by recipients as measured by the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30)(Day 0, Day +28, Day +100, 6 months, 9 months, and 12 months)
研究者
相似试验
撤回
2 期
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AMLRefractory Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaNCT04354025Washington University School of Medicine
招募中
1 期
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell TransplantationMyelodysplastic SyndromesAcute Myeloid LeukemiaMyeloproliferative NeoplasmJuvenile Myelomonocytic LeukemiaNCT04024761Dana-Farber Cancer Institute50
终止
1 期
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)Leukemia, Myeloid, AcuteNCT01898793Washington University School of Medicine89
Unknown
2 期
Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic SyndromeMyelodysplastic SyndromeNCT01673308Ulsan University Hospital35
撤回
1 期
Donor Enriched Activated NK Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid MalignanciesLeukemiaNCT05375253University of Nebraska